Lirafugratinib for solid tumors with FGFR2 fusion
Part of Cancer clinical trials.
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is advanced and cannot be removed by surgery or has spread to other parts of the body.
- Your tumor has an FGFR2 gene fusion or rearrangement (detected by a blood or tumor test).
- You have at least one tumor that can be measured on scans (RECIST criteria).
- You are in good enough health to be up and about (ECOG score 0 or 1).
- You have already tried at least one other cancer treatment (like chemo or immunotherapy) more than 30 days ago.
- You have not taken any FGFR inhibitor drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (3HP-2827) for people with solid tumors that have spread or can't be removed surgically, and have changes in a gene called FGFR2. The goal is to see if the drug is safe and effective.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
Hear when a new FGFR2 Gene Fusion/Rearrangement trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.